A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile

Vaccine. 2009 Nov 5;27(47):6504-11. doi: 10.1016/j.vaccine.2009.07.076. Epub 2009 Aug 7.


Priorix-Tetra (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR (Priorix) and varicella (Varilrix) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into routine vaccination programmes.

Publication types

  • Review

MeSH terms

  • Antibodies, Viral / blood
  • Chickenpox Vaccine / adverse effects
  • Chickenpox Vaccine / immunology*
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Humans
  • Immunization, Secondary
  • Infant
  • Measles-Mumps-Rubella Vaccine / adverse effects
  • Measles-Mumps-Rubella Vaccine / immunology*
  • Vaccines, Combined


  • Antibodies, Viral
  • Chickenpox Vaccine
  • Measles-Mumps-Rubella Vaccine
  • Vaccines, Combined
  • measles, mumps, rubella, varicella vaccine